KLOW Protocol (GHK-Cu + BPC-157 + TB-500 + KPV)
Safety Advisory
Contains multiple active fractions. Potential for site reaction is higher due to complex blend. KPV is theoretically antimicrobial and anti-inflammatory.
Protocol Description
The "Kickstart" blend. Reported research protocols typically aim for daily administration of: GHK-Cu (2mg-5mg), BPC-157 (500mcg), TB-500 (500mcg), and KPV (200mcg-500mcg). This often requires calculating volume based on the specific total vial concentration.
Community Logs
0 VERIFIED ENTRIESNo logs recorded for this protocol yet.
Be the first to contribute data.